Navigation Links
Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
Date:10/6/2008

MOUNTAIN VIEW, Calif. and SEATTLE, Oct. 6 /PRNewswire/ -- Complete Genomics Inc., a newly launched, third-generation human genome sequencing company, and the Institute for Systems Biology (ISB) today announced their partnership to conduct populationwide human genome studies.

In phase one of the project, Complete Genomics will use its proprietary DNA sequencing technology to sequence five genomes from samples provided by ISB. Then, once proof-of-concept has been demonstrated, ISB and Complete Genomics plan to expand this collaboration to sequence the genomes of 100 individuals in 2009 and 2,000 individuals in 2010.

"Using Complete Genomics' human genome sequencing services to gather populationwide human genetic data will allow us to gain a more complete understanding of the genetic components and molecular processes of diseases in order to better manage, treat and prevent human disease and better understand human health," said Dr. Leroy Hood, president of ISB and member of Complete Genomics' Scientific Advisory Board.

"This collaboration demonstrates the value of our sequencing service business model and underscores our vision of using our large-scale, low-cost DNA sequencing technology to elucidate disease pathways," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. "We are pleased to be partnering with such a renowned organization as the Institute for Systems Biology on a project that will provide the data that researchers need to develop better drugs, therapeutics and diagnostics."

About Complete Genomics

Founded in 2006, Complete Genomics is a California company that has developed a novel approach to sequencing human DNA. Complete Genomics plans to combine its proprietary third-generation DNA sequencing technology and its high-performance computing capabilities to create a human genome sequencing service that will deliver low-cost, high-quality data on an unprecedented scale. The company is currently building the world's largest human genome sequencing center. This development will allow pharmaceutical and biotechnology customers, for the first time, to conduct large-scale human genome studies that will help identify the genetic underpinnings of complex diseases and drug responses. For additional information about the company, please visit http://www.completegenomics.com.

About the Institute for Systems Biology

Founded in 2000, the Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. ISB seeks to use systems methods to unravel the complexity of human biology and identify strategies for predicting and preventing significant diseases such as cancer, diabetes and AIDS. ISB's systems approach integrates biology, computation and technological development, focusing on entire, complex biological systems rather than one gene or protein at a time. For more information about ISB, visit http://www.systemsbiology.org.


'/>"/>
SOURCE Complete Genomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
2. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
3. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Recruitment Completed in Ofatumumab NHL Pivotal Study
5. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
8. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
9. DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties
10. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO ... quarter 2017 operating results on Monday, August 7, 2017 ... at 5:00 p.m. ET. ... live broadcast of the conference call by dialing 877-201-0168 ... 51641230 approximately 15 minutes prior to the call. A ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... -- It should come as no surprise to anyone that ... midst of a crippling opioid epidemic. According to the ... overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... from 2001 to 2015". During this time, the prescription rate ... drawing a compelling link between prescription and eventual addiction. The ...
Breaking Medicine Technology:
(Date:7/24/2017)... Los Angeles, CA (PRWEB) , ... July 24, 2017 , ... ... that will spotlight doctors and the cosmetic surgeries they perform on a daily basis. ... in performing the cosmetic surgery procedures they specialize in at their practices. , ...
(Date:7/24/2017)... ... 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, announced ... and divided between two full-time university students enrolled in U.S. or Canadian accredited ... apply for the scholarship, students are asked to submit an essay between 750 ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care product, ... of the leading causes of long term skin conditions, including cancer. In ...
(Date:7/24/2017)... ... 24, 2017 , ... Anyone who uses scales know they have limits; a ... using that same scale to dispense medication. The first example is an issue of ... why it is important to have the right balance for the process. METTLER TOLEDO’s ...
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... Paul ... of the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with ... 10 most valued companies in the world, Allergan is bringing a newly defined structure ...
Breaking Medicine News(10 mins):